Logo image of AMOD

ALPHA MODUS HOLDINGS INC (AMOD) Stock Fundamental Analysis

NASDAQ:AMOD - Nasdaq - US0209521071 - Common Stock - Currency: USD

1.05  -0.06 (-5.41%)

Fundamental Rating

0

AMOD gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 283 industry peers in the Software industry. Both the profitability and financial health of AMOD have multiple concerns. AMOD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AMOD had negative earnings in the past year.
In the past year AMOD has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: AMOD reported negative net income in multiple years.
AMOD had a negative operating cash flow in each of the past 5 years.
AMOD Yearly Net Income VS EBIT VS OCF VS FCFAMOD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 5M 10M

1.2 Ratios

AMOD's Return On Assets of 490.24% is amongst the best of the industry. AMOD outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 490.24%
ROE N/A
ROIC N/A
ROA(3y)80.2%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AMOD Yearly ROA, ROE, ROICAMOD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 200 300 400

1.3 Margins

AMOD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMOD Yearly Profit, Operating, Gross MarginsAMOD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, AMOD has more shares outstanding
The debt/assets ratio for AMOD is higher compared to a year ago.
AMOD Yearly Shares OutstandingAMOD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
AMOD Yearly Total Debt VS Total AssetsAMOD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

AMOD has an Altman-Z score of -157.38. This is a bad value and indicates that AMOD is not financially healthy and even has some risk of bankruptcy.
AMOD has a worse Altman-Z score (-157.38) than 95.76% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -157.38
ROIC/WACCN/A
WACCN/A
AMOD Yearly LT Debt VS Equity VS FCFAMOD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

AMOD has a Current Ratio of 0.13. This is a bad value and indicates that AMOD is not financially healthy enough and could expect problems in meeting its short term obligations.
AMOD has a worse Current ratio (0.13) than 96.82% of its industry peers.
AMOD has a Quick Ratio of 0.13. This is a bad value and indicates that AMOD is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of AMOD (0.13) is worse than 96.82% of its industry peers.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
AMOD Yearly Current Assets VS Current LiabilitesAMOD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for AMOD have decreased strongly by -30.33% in the last year.
The Earnings Per Share has been growing by 61.98% on average over the past years. This is a very strong growth
EPS 1Y (TTM)-30.33%
EPS 3Y61.98%
EPS 5YN/A
EPS Q2Q%72.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMOD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMOD Price Earnings VS Forward Price EarningsAMOD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMOD Per share dataAMOD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AMOD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA MODUS HOLDINGS INC

NASDAQ:AMOD (8/20/2025, 10:55:51 AM)

1.05

-0.06 (-5.41%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-13 2024-11-13
Earnings (Next)N/A N/A
Inst Owners2.1%
Inst Owner Change14.46%
Ins Owners17.79%
Ins Owner Change0%
Market Cap43.23M
AnalystsN/A
Price TargetN/A
Short Float %1.25%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS-0.22
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 490.24%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)80.2%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z -157.38
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.33%
EPS 3Y61.98%
EPS 5YN/A
EPS Q2Q%72.71%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-126.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.13%
OCF growth 3YN/A
OCF growth 5YN/A